Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacodynamics
13 evidence topics · 10 sources
Huntingtin lowering in the striatum and cortex of humanized mice at 7 months
“We show that intrastriatal administration of AAV5-miHTT results in potent and sustained HTT suppression for at least 7 months post-injection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the striatum, we observed a dose-dependent reduction of wtHTT with low, medium and high dose treatments resulting in 42%, 62% and 87% suppression at 7 months post-injection, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, a dose-dependent reduction of wtHTT was also observed in the cortex with low, medium and high dose treatments resulting in 16%, 33% and 62% reduction at 7 months post-injection, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Greater lowering at the injection site than in the cortex
Huntingtin lowering and aggregate suppression in Q175 knock-in mice at 12 months
“A significant dose-dependent average reduction of mutant HTT protein of up to 39% in the striatum and up to 13% in the cortex of Q175 KI mice 12 months after intrastriatal injection of AAV5-miHTT was detected” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AAV5-miHTT caused a dose-dependent and sustained HTT protein reduction with subsequent suppression of mutant HTT aggregate formation in the striatum and cortex.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Motor coordination and survival in R6/2 mice after a single administration
“AAV5-miHTT treatment showed a significant improvement in motor coordination on the rotarod by an increase in latency to fall of 22 s in the high-dose group, which is an increase of 56% compared with vehicle-treated R6/2 mice (one-way ANOVA, p = 0.0226; Figure 6B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One-time AAV5-miHTT administration resulted in a median survival improvement of over 4 weeks compared with untreated R6/2 HD mice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mutant huntingtin messenger RNA and protein lowering in transgenic minipigs
“Both human mutant huntingtin mRNA and protein were significantly reduced in all brain regions transduced by AAV5-miHTT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Consistent with the vector DNA and miHTT expression in the cortex, we also detected a significant reduction of 42.7% (SD ±25.4%; p = 0.0066) more distal in the cortex.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This is the first demonstration of widespread human mutant huntingtin lowering in the large-animal model.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mutant huntingtin protein lowering by brain region and in cerebrospinal fluid in minipigs at 6 and 12 months
“Expression of miHTT strongly correlated with vector DNA, with a corresponding reduction of mutant HTT (mHTT) protein of more than 75% in injected areas, and 30 to 50% lowering in distal regions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“CSF miHTT expression was detected up to 12 months, with CSF mHTT protein lowering of 25 to 30% at 6 and 12 months after dosing.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Regional mutant huntingtin lowering reported by the sponsor at 12 months in minipigs
Huntingtin messenger RNA and protein lowering in patient-derived neurons
Reduction of exon 1 huntingtin messenger RNA and protein in two mouse models
“Intrastriatal administration of AAV5-miHTT resulted in dose-dependent expression of mature miHTT microRNA in cortical brain regions, accompanied by significant lowering of both FL HTT and HTT1a mRNA expression at 2 months postinjection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mutant HTT and HTTexon1 protein levels were also significantly reduced in the striatum and cortex of heterozygous zQ175 knock-in mice at 2 months after AAV5-miHTT treatment and in humanized Hu128/21 mice 7 months post-treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These data demonstrate that, in addition to FL HTT, AAV5-miHTT also effectively reduces the highly pathogenic HTTexon1 protein in HD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Neurochemical and volumetric markers in homozygous Q175FDN mice
“High dose AAV5-miHTT treatment partially rescued tNAA depletion (P = 0.0003) (Fig. 6A), and tNAA concentrations in high dose-treated animals were restored to near-wild-type levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AAV5-miHTT partially rescues regional volume loss in brains of 6-month-old homozygous Q175FDN mice” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, gene expression analysis by RNA sequencing revealed a distinct transcriptional phenotype associated with mutant HTT expression in the striatum that was partially rescued by high dose AAV5-miHTT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Plasma neurofilament light chain unchanged by treatment in homozygous Q175FDN mice
“Plasma neurofilament light was elevated in homozygous Q175FDN mice (P < 0.0001) but was unchanged by AAV5-miHTT (Supplementary Tables 22 and 23), indicating that HTT lowering in the brain does not affect peripheral abundance of neurofilament light in this model.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is also possible that plasma neurofilament light may decrease with a longer treatment duration, and that our experimental timeline was too brief to capture the full effect of AAV5-miHTT therapy on this outcome measure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exploratory pharmacodynamic biomarkers in the U.S. study: mutant huntingtin and neurofilament light chain in cerebrospinal fluid
| Field | Quoted record |
|---|---|
| Exploratory outcome measure | “CSF Mutant Protein (fM)” |
| Exploratory outcome measure | “CSF/Serum Neurofilament Light Chain (pg/mL)” |
| Measure description of each | “Will be used as an exploratory biomarker to measure disease progression and responsiveness to AMT-130 treatment.” |
Durability marker: engineered microRNA in cerebrospinal fluid extracellular vesicles up to two years in non-human primates
“Quantifiable engineered microRNA levels enriched in extracellular vesicles were detected in the CSF up to two years after brain infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Altogether, these results confirm the long-term expression of adeno-associated viral vector serotype 5-delivered microRNAs and support the use of extracellular vesicle-associated microRNAs as novel translational pharmacokinetic markers in ongoing clinical trials of gene therapies for neurodegenerative diseases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote